Cargando…

Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel

Dasabuvir is mainly metabolized by cytochrome P450 (CYP) 2C8 and is predominantly used in a regimen containing ritonavir. Ritonavir and clopidogrel are inhibitors of CYP3A4 and CYP2C8, respectively. In a randomized, crossover study in 12 healthy subjects, we examined the impact of clinical doses of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Itkonen, Matti K., Tornio, Aleksi, Lapatto‐Reiniluoto, Outi, Neuvonen, Mikko, Neuvonen, Pertti J., Niemi, Mikko, Backman, Janne T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585621/ https://www.ncbi.nlm.nih.gov/pubmed/29696643 http://dx.doi.org/10.1002/cpt.1099

Ejemplares similares

Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8‐Mediated Metabolism of Montelukast in Humans
por: Itkonen, Matti K., et al.
Publicado: (2017)

Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin
por: Lehtisalo, Minna, et al.
Publicado: (2020)

Itraconazole Increases Ibrutinib Exposure 10‐Fold and Reduces Interindividual Variation—A Potentially Beneficial Drug‐Drug Interaction
por: Tapaninen, Tuija, et al.
Publicado: (2019)

Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans
por: Neuvonen, Mikko, et al.
Publicado: (2021)

Incidence, preventability, and causality of adverse drug reactions at a university hospital emergency department
por: Kauppila, Mirjam, et al.
Publicado: (2020)

Pharmacogenomics of celiprolol – evidence for a role of P‐glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics
por: Hirvensalo, Päivi, et al.
Publicado: (2021)

Enantiospecific Pharmacogenomics of Fluvastatin
por: Hirvensalo, Päivi, et al.
Publicado: (2019)

Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics
por: Hirvensalo, Päivi, et al.
Publicado: (2017)

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease
por: Bernstein, David E., et al.
Publicado: (2018)

Genomewide Association Study of Simvastatin Pharmacokinetics
por: Mykkänen, Anssi J. H., et al.
Publicado: (2022)

A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics
por: Lehtisalo, Minna, et al.
Publicado: (2022)

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4
por: Leung, Daniel H., et al.
Publicado: (2018)

Clinical Studies on Drug–Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation
por: Tornio, Aleksi, et al.
Publicado: (2019)

Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients
por: Loo, Nicole, et al.
Publicado: (2019)

Medicines, environment and clinical pharmacology
por: Lapatto‐Reiniluoto, Outi, et al.
Publicado: (2022)

Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin
por: Feld, Jordan J., et al.
Publicado: (2018)

Interaction of Dasabuvir With Clopidogrel: Did Predictions by Physiologically Based Pharmacokinetics Modeling Pass the Test?
por: Shebley, Mohamad
Publicado: (2018)

Rifampin Reduces the Plasma Concentrations of Oral and Intravenous Hydromorphone in Healthy Volunteers
por: Lohela, Terhi J., et al.
Publicado: (2020)

Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders
por: Fuchs, Michael, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug–Drug Interaction Between Clopidogrel and Dasabuvir
por: Shebley, M, et al.
Publicado: (2017)

Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus
por: Danilau, Dzmitry, et al.
Publicado: (2017)

Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
por: Wu, Jingjing, et al.
Publicado: (2019)

Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection
por: Pogorzelska, Joanna, et al.
Publicado: (2016)

Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents
por: Shiffman, Mitchell L, et al.
Publicado: (2016)

Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection
por: Smith, Michael A, et al.
Publicado: (2015)

Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial
por: Deutsch, Liat, et al.
Publicado: (2020)

Identification of Glycochenodeoxycholate 3‐O‐Glucuronide and Glycodeoxycholate 3‐O‐Glucuronide as Highly Sensitive and Specific OATP1B1 Biomarkers
por: Neuvonen, Mikko, et al.
Publicado: (2020)

On-Treatment Elevation in Hepatic Transaminases during HCV Treatment with Ombitasvir, Paritaprevir, Dasabuvir, Ritonavir, and Ribavirin: A Case Series
por: Bean, Madelyne, et al.
Publicado: (2016)

Effectiveness and Safety of Sofosbuvir/Ledipasvir and Paritaprevir/ritonavir/Ombitasvir + Dasabuvir in Patients with Chronic Kidney Diseases: Results from ERCHIVES
por: Butt, Adeel, et al.
Publicado: (2017)

Fibrosis Progression and Incidence of Cirrhosis and Hepatic Decompensation in Persons Treated with Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir: Results from ERCHIVES
por: Simon, Tracey, et al.
Publicado: (2017)

Safety and Efficacy of Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir for Hepatitis C Virus Infection Across All Levels of Kidney Function
por: Sise, Meghan E.
Publicado: (2018)

Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study
por: Leventer-Roberts, Maya, et al.
Publicado: (2017)

Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C – a real-world study
por: Simon, Krzysztof Adam, et al.
Publicado: (2019)

Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review
por: Hussaini, Trana
Publicado: (2016)

Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy
por: Hunyady, Béla, et al.
Publicado: (2018)

Investigating Real‐World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records
por: Tornio, Aleksi, et al.
Publicado: (2017)

Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low‐dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis
por: Poordad, Fred, et al.
Publicado: (2019)

Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification
por: Krauss, Markus, et al.
Publicado: (2013)

Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir
por: Krishnan, Preethi, et al.
Publicado: (2015)

Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients
por: Taramasso, Lucia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sv9hmogs3u11fspqetc9gj0fq0